JBIO: the cash flow

MyFinsight

For the quarter ending 2025-09-30, JBIO had -$170,836K decrease in cash & cash equivalents over the period. -$22,181K in free cash flow.

Cash Flow	2025-09-30	2025-06-30
Net loss	-25,175	-70,303
Change in fair value of convertible notes payable	0	21,584
Stock-based compensation	4,295	6,318
Non-cash lease expense	-17	74
Accretion/amortization on investments	174	-
Depreciation expense	12	5
Prepaid expenses and other current assets	413	1,358
Other assets	-	-88
Accounts payable	-4,878	4,938
Accrued expenses and other current liabilities	4,578	2,862
Operating lease liabilities	68	-
Related party accrued expenses and other current liabilities	-332	-3,124
Net cash used in operating activities	-22,124	-38,916
Purchases of investments	148,592	-
Payment of security deposit	59	-
Purchases of property and equipment	57	136
Net cash used in investing activities	-148,708	-136
Proceeds from the pre-closing financing, net of 14,548 of offering costs	0	190,452
Cash acquired in connection with the reverse recapitalization	0	156
Net cash provided by financing activities	0	190,608
Effect on exchange rates on cash and cash equivalents	-4	-
Net (decrease) increase in cash and cash equivalents	-170,836	151,556
Cash and cash equivalents at beginning of period	69,386	-
Cash and cash equivalents at end of period	50,106	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.